Table of Contents Author Guidelines Submit a Manuscript
Cardiology Research and Practice
Volume 2011, Article ID 316927, 8 pages
http://dx.doi.org/10.4061/2011/316927
Research Article

Cardiac Function in Long-Term Survivors of Childhood Lymphoma

1Department of Pediatrics, Meyer Children's Hospital, Rambam Medical Center, Technion-Israel Institute of Technology, Haifa 31096, Israel
2Division of Obstetrics and Gynecology, Meyer Children's Hospital, Rambam Medical Center, Technion-Israel Institute of Technology, Haifa 31096, Israel
3Department of Pediatric Hematology and Oncology, Meyer Children's Hospital, Rambam Medical Center, Technion-Israel Institute of Technology, Haifa 31096, Israel
4Unit of Pediatric Cardiology, Meyer Children's Hospital, Rambam Medical Center, Technion-Israel Institute of Technology, Haifa, 31096, Israel

Received 3 November 2010; Revised 4 January 2011; Accepted 4 January 2011

Academic Editor: Dirk Westermann

Copyright © 2011 Mark K. Friedberg et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. L. Hancock, S. S. Donaldson, and R. T. Hoppe, “Cardiac disease following treatment of Hodgkin's disease in children and adolescents,” Journal of Clinical Oncology, vol. 11, no. 7, pp. 1208–1215, 1993. View at Google Scholar · View at Scopus
  2. M. A. Grenier and S. E. Lipshultz, “Epidemiology of anthracycline cardiotoxicity in children and adults,” Seminars in Oncology, vol. 25, no. 4, pp. 72–85, 1998. View at Google Scholar · View at Scopus
  3. T. J. Porea, Z. E. Dreyer, J. T. Bricker, and D. H. Mahoney, “Evaluation of left ventricular function in asymptomatic children about to undergo anthracycline-based chemotherapy for acute leukemia: an outcome study,” Journal of Pediatric Hematology/Oncology, vol. 23, no. 7, pp. 420–423, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. M. T. Meinardi, W. T. A. Van Der Graaf, D. J. Van Veldhuisen, J. A. Gietema, E. G. E. De Vries, and D. TH. Sleijfer, “Detection of anthracycline-induced cardiotoxicity,” Cancer Treatment Reviews, vol. 25, no. 4, pp. 237–247, 1999. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. R. B. Devereux and N. Reichek, “Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method,” Circulation, vol. 55, no. 4, pp. 613–618, 1977. View at Google Scholar · View at Scopus
  6. N. H. Silverman, Pediatric Echocardiography, Williams & Wilkins, Baltimore, Md, USA, 1st edition, 1993.
  7. J. P. Krischer, S. Epstein, D. D. Cuthbertson, A. M. Goorin, M. L. Epstein, and S. E. Lipshultz, “Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience,” Journal of Clinical Oncology, vol. 15, no. 4, pp. 1544–1552, 1997. View at Google Scholar · View at Scopus
  8. C. Putterman and A. Polliack, “Late cardiovascular and pulmonary complications of therapy in Hodgkin's disease: report of three unusual cases, with a review of relevant literature,” Leukemia and Lymphoma, vol. 7, no. 1-2, pp. 109–115, 1992. View at Google Scholar · View at Scopus
  9. J. Leandro, J. Dyck, D. Poppe et al., “Cardiac dysfunction late after cardiotoxic therapy for childhood cancer,” American Journal of Cardiology, vol. 74, no. 11, pp. 1152–1156, 1994. View at Publisher · View at Google Scholar · View at Scopus
  10. K. Nysom, K. Holm, S. R. Lipsitz et al., “Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia,” Journal of Clinical Oncology, vol. 16, no. 2, pp. 545–550, 1998. View at Google Scholar · View at Scopus
  11. L. C. M. Kremer, E. C. Van Dalen, M. Offringa, J. Ottenkamp, and P. A. Voûte, “Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study,” Journal of Clinical Oncology, vol. 19, no. 1, pp. 191–196, 2001. View at Google Scholar · View at Scopus
  12. L. J. Steinherz, P. G. Steinherz, C. T. C. Tan, G. Heller, and M. L. Murphy, “Cardiac toxicity 4 to 20 years after completing anthracycline therapy,” Journal of the American Medical Association, vol. 266, no. 12, pp. 1672–1677, 1991. View at Publisher · View at Google Scholar · View at Scopus
  13. P. K. Singal and N. Iliskovic, “Doxorubicin-induced cardiomyopathy,” New England Journal of Medicine, vol. 339, no. 13, pp. 900–905, 1998. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. M. N. Prout, M. J. S. Richards, and K. Ja Chung, “Adriamycin cardiotoxicity in children. Case reports, literature review, and risk factors,” Cancer, vol. 39, no. 1, pp. 62–65, 1977. View at Google Scholar · View at Scopus
  15. A. C. Gilladoga, C. Manuel, C. T. Tan, N. Wollner, S. S. Sternberg, and M. L. Murphy, “The cardiotoxcicity of adriamycin and daunomycin in children,” Cancer, vol. 37, no. 2, supplement, pp. 1070–1078, 1976. View at Google Scholar
  16. D. D. Von Hoff, M. W. Layard, and P. Basa, “Risk factors for doxorubicin-induced congestive heart failure,” Annals of Internal Medicine, vol. 91, no. 5, pp. 710–717, 1979. View at Google Scholar
  17. R. A. Minow, R. S. Benjamin, and J. A. Gottlieb, “Adriamycin cardiomyopathy: an overview with determination of risk factors,” Cancer Chemotherapy Reports, vol. 6, no. 2, pp. 195–201, 1975. View at Google Scholar · View at Scopus
  18. J. R. Kushner, V. L. Hansen, S. P. Hammer, and R. N. Matthews, “Cardiomyopathy after widely seperated courses of adriamycin exacerbated by actinomycin D and mithramycin,” Cancer Treatment Reports, vol. 36, pp. 1577–1584, 1975. View at Google Scholar
  19. P. J. Smith, H. Ekert, K. D. Waters, and R. N. Matthews, “High incidence of cardiomyopathy in children treated with adriamycin and DTIC in combination chemotherapy,” Cancer Treatment Reports, vol. 61, no. 9, pp. 1736–1738, 1977. View at Google Scholar
  20. S. A. Crone, Y. Y. Zhao, L. Fan et al., “ErbB2 is essential in the prevention of dilated cardiomyopathy,” Nature Medicine, vol. 8, no. 5, pp. 459–465, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. C. S. LaMonte, S. D. J. Yeh, and D. J. Straus, “Long-term follow-up of cardiac function in patients with Hodgkin's disease treated with mediastinal irradiation and combination chemotherapy including doxorubicin,” Cancer Treatment Reports, vol. 70, no. 4, pp. 439–444, 1986. View at Google Scholar · View at Scopus
  22. L. S. Constine, R. G. Schwartz, D. E. Savage, V. King, and A. Muhs, “Cardiac function, perfusion, and morbidity in irradiated long-term survivors of Hodgkin's disease,” International Journal of Radiation Oncology Biology Physics, vol. 39, no. 4, pp. 897–906, 1997. View at Publisher · View at Google Scholar · View at Scopus
  23. M. B. Lund, H. Ihlen, B. M.R. Voss et al., “Increased risk of heart valve regurgitation after mediastinal radiation for Hodgkin's disease: an echocardiographic study,” Heart, vol. 75, no. 6, pp. 591–595, 1996. View at Google Scholar
  24. J. D. R. Thomson, J. Allen, and J. L. Gibbs, “Left sided valvar regurgitation in normal children and adolescents,” Heart, vol. 83, no. 2, pp. 185–187, 2000. View at Google Scholar
  25. J. Allen, J. D. R. Thomson, I. J. Lewis, and J. L. Gibbs, “Mitral regurgitation after anthracycline treatment for childhood malignancy,” Heart, vol. 85, no. 4, pp. 430–432, 2001. View at Google Scholar
  26. L. J. Steinherz, P. G. Steinherz, and C. Tan, “Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients,” Medical and Pediatric Oncology, vol. 24, no. 6, pp. 352–361, 1995. View at Google Scholar
  27. T. Nousiainen, E. Vanninen, A. Rantala, E. Jantunen, and J. Hartikainen, “QT dispersion and late potentials during doxorubicin therapy for non-hodgkin's lymphoma,” Journal of Internal Medicine, vol. 245, no. 4, pp. 359–364, 1999. View at Publisher · View at Google Scholar
  28. C. L. Schwartz, W. L. Hobbie, S. Truesdell, L. C. Constine, and E. B. Clark, “Corrected QT interval prolongation in anthracycline-treated survivors of childhood cancer,” Journal of Clinical Oncology, vol. 11, no. 10, pp. 1906–1910, 1993. View at Google Scholar
  29. J. Leandro, J. Dyck, D. Poppe et al., “Cardiac dysfunction late after cardiotoxic therapy for childhood cancer,” American Journal of Cardiology, vol. 74, no. 11, pp. 1152–1156, 1994. View at Publisher · View at Google Scholar
  30. D. L. Keefe, “Anthracycline-induced cardiomyopathy,” Seminars in Oncology, vol. 28, no. 4, pp. 2–7, 2001. View at Google Scholar
  31. R. L. Larsen, R. I. Jakacki, V. L. Vetter, A. T. Meadows, J. H. Silber, and G. Barber, “Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults,” American Journal of Cardiology, vol. 70, no. 1, pp. 73–77, 1992. View at Publisher · View at Google Scholar
  32. J. F. Boivin, G. B. Hutchison, J. H. Lubin, and P. Mauch, “Coronary artery disease mortality in patients treated for Hodgkin's disease,” Cancer, vol. 69, no. 5, pp. 1241–1247, 1992. View at Google Scholar
  33. K. M. Weesner, M. Bledsoe, A. Chauvenet, and M. Wofford, “Exercise echocardiography in the detection of anthracycline cardiotoxicity,” Cancer, vol. 68, no. 2, pp. 435–438, 1991. View at Google Scholar
  34. R. G. Martin, J. C. Ruckdeschel, and P. Chang, “Radiation related pericarditis,” American Journal of Cardiology, vol. 35, no. 2, pp. 216–220, 1975. View at Google Scholar
  35. D. I. Scott and R. D. Thomas, “Late onset constrictive pericarditis after thoracic radiotherapy,” British Medical Journal, vol. 1, no. 6109, pp. 341–342, 1978. View at Google Scholar
  36. S. E. Lipshultz, R. E. Scully, S. R. Lipsitz et al., “Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial,” The Lancet Oncology, vol. 11, no. 10, pp. 950–961, 2010. View at Publisher · View at Google Scholar
  37. G. Chvetzoff, B. Bonnotte, and B. Chauffert, “Anticancer chemotherapy: prevention of toxicityChimiotherapie anticancereuse: prevention de la toxicite,” Presse Medicale, vol. 27, no. 39, pp. 2106–2112, 1998. View at Google Scholar